Abstract
Similar to other pathogens, HIV can directly activate the complement pathway even in the absence of antibodies. During and after seroconversion, HIV-specific antibodies enhance the activation of complement and increase deposition of complement fragments on virions dramatically. However, even in the presence of HIV-specific antibodies, no or only poor lysis occurs. HIV has adapted different protection mechanisms to keep complement activation under the threshold necessary to induce virolysis. In addition to its own envelope proteins, the viral envelope contains membrane-anchored host molecules. Among those are complement regulatory proteins that remain functionally active on the surface of HIV and turn down the complement cascade. In addition, serum proteins with complement regulatory activities become secondarily attached onto the virus, thereby enhancing the protection of HIV against complement-mediated damage. Therefore, opsonised virions accumulate in HIV-infected individuals, which subsequently interact with complement receptor (CR) expressing cells. This review is mainly focused on these interactions, which result either in infection of CR-positive cells with high efficiency, or retention of viral particles on their surface via CRs, thereby promoting transmission of virus to other permissive cells.
Keywords: HIV Infection, Cell Perturbations, C5a Receptor
Current Molecular Medicine
Title: Complement Receptors in HIV Infection
Volume: 2 Issue: 8
Author(s): S. Doepper, L. Kacani, B. Falkensammer, M. P. Dierich and H. Stoiber
Affiliation:
Keywords: HIV Infection, Cell Perturbations, C5a Receptor
Abstract: Similar to other pathogens, HIV can directly activate the complement pathway even in the absence of antibodies. During and after seroconversion, HIV-specific antibodies enhance the activation of complement and increase deposition of complement fragments on virions dramatically. However, even in the presence of HIV-specific antibodies, no or only poor lysis occurs. HIV has adapted different protection mechanisms to keep complement activation under the threshold necessary to induce virolysis. In addition to its own envelope proteins, the viral envelope contains membrane-anchored host molecules. Among those are complement regulatory proteins that remain functionally active on the surface of HIV and turn down the complement cascade. In addition, serum proteins with complement regulatory activities become secondarily attached onto the virus, thereby enhancing the protection of HIV against complement-mediated damage. Therefore, opsonised virions accumulate in HIV-infected individuals, which subsequently interact with complement receptor (CR) expressing cells. This review is mainly focused on these interactions, which result either in infection of CR-positive cells with high efficiency, or retention of viral particles on their surface via CRs, thereby promoting transmission of virus to other permissive cells.
Export Options
About this article
Cite this article as:
Doepper S., Kacani L., Falkensammer B., Dierich P. M. and Stoiber H., Complement Receptors in HIV Infection, Current Molecular Medicine 2002; 2 (8) . https://dx.doi.org/10.2174/1566524023361826
DOI https://dx.doi.org/10.2174/1566524023361826 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Small Molecules that Promote Neurogenesis in vitro
Recent Patents on CNS Drug Discovery (Discontinued) Alkaloids from Cyanobacteria with Diverse Powerful Bioactivities
Mini-Reviews in Medicinal Chemistry New Approaches to Develop Drug Treatment for Alzheimer’s Disease: Targeting Calcium Dysregulation
Current Alzheimer Research Surgical or Interventional Revascularization in Diabetic Patients with Coronary Artery Disease?
Current Diabetes Reviews Genetic Editing and Pharmacogenetics in Current And Future Therapy Of Neurocognitive Disorders
Current Alzheimer Research Proteome Adjustments Post Gradual Hypoxic Stress in Barilius bendelisis: Insights into Adaptive Strategies of a Hill Stream Cyprinid
Current Proteomics Hypertension in 2017: Update in Treatment and Pharmaceutical Innovations
Current Pharmaceutical Design Treatment of Chronic Hepatitis B: From Research to Clinical Practice Via the Consensus Conferences
Current Pharmaceutical Design Oxidative Stress and Opioids' Toxicity: An Update
Mini-Reviews in Organic Chemistry Opportunities to Improve the Prevention and Treatment of Cervical Cancer
Current Molecular Medicine Anticancer Drug-Induced Immunomodulation and Cancer Therapeutics
Current Cancer Therapy Reviews Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Current Pharmaceutical Design Synthesis, Biological Evaluation and Pharmacokinetic Studies of Mefenamic Acid - N-Hydroxymethylsuccinimide Ester Prodrug as Safer NSAID
Medicinal Chemistry Patent Selections
Recent Patents on Medical Imaging The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction
Current Vascular Pharmacology Interleukin-1β Receptor Antagonism Prevents Cognitive Impairment Following Experimental Bacterial Meningitis
Current Neurovascular Research Patient Impressions of Possible Catastrophic Outcomes after Diabetic Foot Ulceration
Current Diabetes Reviews Clinical Aspects of Melatonin Intervention in Alzheimers Disease Progression
Current Neuropharmacology Currently Used Antimycotics: Spectrum, Mode of Action and Resistance Occurrence
Current Drug Targets Electroporation: An Avenue for Transdermal Drug Delivery
Current Drug Delivery